Anti-Biotherapeutic Antibody Development
against Ipilimumab with HuCAL PLATINUM®

Request Your Free Digital Poster (PDF)

This poster presents the typical workflow for Bio-Rad's anti-idiotypic antibody projects using generation and characterization of antibodies against the checkpoint inhibitor drug ipilimumab (YERVOY) as an example.

Antibodies in monovalent Fab format were characterized for specificity, affinity, and inhibitory potential, and were screened for their ability to work in a pharmacokinetic bridging ELISA for drug quantification. Selected Fab antibodies were converted into full length, fully human IgG1 format and evaluated in an anti-drug-antibody bridging ELISA.

Inhibitory antibodies that recognize the free drug, and antibodies that recognize the drug-target complex were developed and are available in our catalog.

Get anti-ipilimumab antibodies

Need anti-idiotypic antibodies to your original biologic?


Receive updates on resources like this straight into your inbox...

Sign up to receive our emailers by submitting the form on the right, to get updates on:

  • Case studies sharing our customers' successes
  • Application notes
  • Video interviews with antibody experts
  • Updates on new anti-biotherapeutic antibodies launched
  • New custom services available

We are constantly expanding our range of antibodies and reagents, resources, and online tools to help you choose the right antibodies, and design experiments with confidence so you can achieve more.

Follow Us

facebook icon
twitter icon
linkedin icon
youtube icon
pinterest icon
RSS icon
wechat icon

Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. HuCAL and HuCAL PLATINUM are trademarks of MorphoSys AG. All trademarks used herein are the property of their respective owner.

Request the Poster PDF
Schedule a Call With Specialist

Thank you

Please download the PDF here